查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046907

皮膚病學合約研究機構市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、按服務類型、按地區和競爭對手分類，2021-2031年

Dermatology Contract Research Organization Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Service Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球皮膚病學領域的合約研究組織 (CRO) 市場預計將從 2025 年的 55.8 億美元成長到 2031 年的 82.4 億美元，複合年成長率為 6.71%。

這些專業機構專門為皮膚科藥物和醫療設備提供臨床試驗管理和監管支持，利用其在試驗設計方面的專業知識，加速銀屑病等疾病治療方法的研發。皮膚病在全球日益普遍，進而需要增加研究經費，推動了這一領域的成長。根據國際皮膚病學會聯盟 (ILDS) 2024 年的報告，“皮膚病影響著全球超過 30 億人，是導致非致命性疾病負擔的第四大原因”，這凸顯了龐大的患者群體對專業外包服務的需求，以應對日益成長的臨床試驗數量。

市場概覽
預測期 2027-2031
市場規模：2025年 55.8億美元
市場規模：2031年 82.4億美元
複合年成長率：2026-2031年 6.71%
成長最快的細分市場 臨床
最大的市場 北美洲

然而，全球各國監管合規的日益複雜化為市場擴張帶來了重大障礙。監管機構強制執行的嚴格安全要求往往導致核准時間延長、臨床試驗成本增加，造成沉重的監管負擔。因此，合約研究組織（CRO）被迫維護龐大的合規體系，這不僅會消耗其現有資源，還可能最終延緩創新皮膚病療法的上市。

市場促進因素

該市場的主要驅動力是生物製藥領域新型皮膚病治療藥物研發的蓬勃發展。隨著企業從傳統的局部用藥轉向針對異位性皮膚炎等疾病的複雜生物製藥，對專業外包服務的需求日益成長。這種向嚴謹臨床試驗的轉變得到了大量投資的支持。例如，LEO Pharma在其2024年2月發布的「2023年度報告」中，累計18.74億丹麥克朗用於研發，以推進其皮膚病治療產品線，這凸顯了該行業對合約研究組織（CRO）在管理複雜試驗方面的依賴。此外，這些創新藥物的商業性可行性也推動了進一步的研究。正如賽諾菲在2024年報告的那樣，其生物製藥Dupixent僅在第三季度的銷售額就接近35億歐元，這表明其皮膚病產品組合具有良好的盈利。

美容和皮膚科領域的擴張進一步豐富了市場。在該領域，消費者對注射等非侵入性療法的需求日益成長，促使生產商進行大規模臨床試驗以獲得監管部門的核准。這個快速成長的產業依賴合約研究組織 (CRO) 來管理特定的安全性和有效性標準，而全球龐大的治療量也凸顯了這一需求。根據國際美容整形外科學會 (ISAPS) 於 2024 年 6 月發布的《全球美容和皮膚科手術調查》，2023 年全球約進行了 3490 萬例美容手術，這催生了對新型美容產品臨床療效測試的需求，進而擴大了專注於皮膚科的 CRO 的業務範圍。

市場挑戰

全球皮膚病學合約研究組織 (CRO) 市場面臨的主要阻礙因素是，跨多個司法管轄區遵守法規的難度日益增加。 CRO 的目標是進行多區域臨床試驗，以涵蓋異位性皮膚炎和銀屑病等疾病的不同患者群體，但它們面臨著法規分散、指南衝突的局面，這需要擴展合規架構並對法律團隊進行大量投資。這些監管差異分散了資金，使其無法用於核心研究活動，而各地區複雜的安全性報告標準和資料隱私合規要求也必然會延長試驗啟動流程並增加營運成本。

為因應潛在的監管詢問而採取的主動資料收集策略進一步加劇了這一負擔，增加了試驗實施的複雜性。 TransCelerate BioPharma 2025 年的報告指出，「在高達 32.5% 的 III 期臨床試驗中收集的患者數據來自與主要終點或關鍵次要終點沒有直接關聯的程序。」 由於滿足嚴格的合規要求，大量非必要數據成為皮膚病領域合約研究組織 (CRO) 的物流瓶頸，最終導致新治療方法的核准和後續皮膚病商業化。

市場趨勢

分散式和混合式臨床試驗模式的普及正在從根本上改變全球皮膚病學合約研究組織 (CRO) 市場，消除患者參與的地理障礙。隨著越來越多的研究尋求納入不同膚質的患者群體以檢驗療效，CRO 正在利用遠端監測技術和虛擬訪視來提高受試者的招募率和保留率。這種轉變使更多人能夠參與臨床試驗，同時透過減少對實體試驗設施的需求來最佳化申辦者的效率。 Medable 公司在 2025 年 6 月發布的題為「Medable 推出合作夥伴計劃，協助快速推出臨床試驗」的新聞稿中重點介紹了這項營運改進，並指出使用該公司分散式平台的客戶已取得顯著成果，包括臨床試驗成本降低 50%。

同時，將人工智慧驅動的皮膚影像診斷技術應用於客觀的病變分析正成為一項關鍵趨勢，旨在解決傳統皮膚病學評估中固有的主觀性問題。透過使用機器學習演算法分析高解析度影像，合約研究組織（CRO）可以為黑色素瘤和銀屑病等疾病提供標準化評分，從而最大限度地減少研究人員之間的評分差異，並確保更可靠的數據終點。梅奧診所平台在其2025年10月發表的報導《皮膚病學領域人工智慧的最新進展》中強調了這項技術進步的價值。文章報導，近期評估的人工智慧模型在檢測早期黑色素瘤方面比臨床醫師高出10%以上，充分展現了這些工具為臨床研究帶來的卓越診斷準確性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：皮膚病領域合約研究組織（CRO）的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（藥物發現、臨床前、臨床）
    • 服務類型（實驗室、技術、醫學寫作、法規及醫學事務、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美皮膚病學合約研究組織（CRO）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲皮膚病領域合約研究組織（CRO）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區皮膚病學合約研究組織（CRO）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲皮膚病領域合約研究組織（CRO）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲皮膚病學合約研究組織（CRO）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球皮膚科合約研究組織（CRO）市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • IQVIA, Inc
  • Aragen Life Sciences Ltd
  • Thermo Fisher Scientific Inc.
  • Parexel International Corporation
  • Charles River Laboratories
  • Icon, Plc
  • Medidata Solutions
  • Syneos Health pvt ltd.
  • S Pharmaron inc.
  • Wuxi Apptec

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19782

The Global Dermatology Contract Research Organization (CRO) Market is projected to expand from USD 5.58 Billion in 2025 to USD 8.24 Billion by 2031, reflecting a CAGR of 6.71%. These specialized organizations provide essential clinical trial management and regulatory support specifically tailored for dermatological drugs and devices, utilizing their expertise in study design to expedite the development of treatments for conditions such as psoriasis. This growth is underpinned by the increasing global prevalence of skin disorders, which necessitates higher research expenditure; according to the 'International League of Dermatological Societies' in '2024', 'skin diseases affect more than three billion people worldwide and stand as the fourth leading cause of non-fatal disease burden', highlighting the massive patient base that drives the demand for specialized outsourcing services to handle the rising volume of clinical studies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.58 Billion
Market Size 2031USD 8.24 Billion
CAGR 2026-20316.71%
Fastest Growing SegmentClinical
Largest MarketNorth America

However, market expansion faces a significant hurdle due to the escalating complexity of regulatory compliance across various global jurisdictions. Strict safety requirements mandated by authorities often result in prolonged approval timelines and increased trial costs, creating a substantial regulatory burden. Consequently, CROs are compelled to maintain extensive compliance infrastructures, a necessity that can strain available resources and ultimately delay the commercialization of innovative dermatological therapies.

Market Driver

The market is primarily driven by a surge in biopharmaceutical R&D for novel dermatologics, which increases the need for specialized outsourcing as companies transition from traditional topicals to complex biologics for conditions like atopic dermatitis. This shift toward rigorous clinical testing is evidenced by significant financial investments; for instance, LEO Pharma, in its 'Annual Report 2023' released in February 2024, allocated DKK 1,874 million to research and development to progress its medical dermatology pipeline, highlighting the industry's dependence on CROs for managing complex studies. Additionally, the commercial viability of these innovations fuels further research, as demonstrated by Sanofi, which reported in 2024 that sales of its biologic Dupixent reached nearly €3.5 billion in the third quarter alone, confirming the lucrative nature of dermatological portfolios.

Further diversifying the market is the expansion of the cosmetic and aesthetic dermatology sector, where rising consumer demand for non-invasive procedures like injectables compels manufacturers to undertake extensive clinical trials for regulatory approval. This flourishing segment depends on CROs to manage specific safety and efficacy standards, a need supported by the substantial volume of treatments performed globally. According to the 'Global Survey on Aesthetic/Cosmetic Procedures' by the International Society of Aesthetic Plastic Surgery in June 2024, approximately 34.9 million aesthetic procedures were conducted worldwide in 2023, creating a parallel demand for the clinical validation of new aesthetic products and thereby broadening the operational scope of dermatology-focused CROs.

Market Challenge

A major restraint on the Global Dermatology Contract Research Organization (CRO) Market is the escalating difficulty of navigating regulatory compliance across multiple global jurisdictions. As CROs aim to conduct multi-regional clinical trials to reach diverse patient populations for diseases like atopic dermatitis and psoriasis, they face a fragmented environment of conflicting guidelines that necessitates heavy investment in expanded compliance infrastructures and legal teams. This regulatory divergence diverts capital away from core research activities, while the requirement to adhere to intricate safety reporting standards and data privacy laws in each region inevitably lengthens trial initiation processes and raises operational overhead.

The burden is further aggravated by the use of defensive data collection strategies designed to address potential regulatory inquiries, which adds complexity to trial execution. According to 'TransCelerate BioPharma' in '2025', 'up to 32.5% of patient data collected in phase 3 trials comes from procedures that do not directly support primary or key secondary endpoints'. This overwhelming amount of non-essential data, resulting from the pressure to satisfy rigorous compliance expectations, creates logistical bottlenecks for Dermatology CROs and ultimately slows down the approval and subsequent commercialization of new dermatological therapies.

Market Trends

The widespread adoption of decentralized and hybrid clinical trial models is fundamentally transforming the Global Dermatology Contract Research Organization (CRO) Market by removing geographical barriers to patient participation. As studies increasingly demand diverse patient populations to verify efficacy across different skin types, CROs are utilizing remote monitoring technologies and virtual visits to improve recruitment and retention, a shift that democratizes trial access while optimizing sponsor efficiency by reducing the need for physical sites. This operational improvement is highlighted by Medable Inc. in a June 2025 press release titled 'Medable Launches Partner Program for Faster Clinical Trial Startup', which noted that customers using its decentralized platform achieved significant results, including a 50% reduction in clinical trial costs.

Concurrently, the integration of AI-powered skin imaging for objective lesion analysis is becoming a pivotal trend, addressing the subjectivity common in traditional dermatological assessments. By employing machine learning algorithms to analyze high-resolution images, CROs can provide standardized scoring for conditions such as melanoma and psoriasis, thereby minimizing inter-rater variability among investigators and ensuring more reliable data endpoints. The value of this technological advancement is underscored by the Mayo Clinic Platform in the October 2025 article 'The Latest AI Developments in Dermatology', which reported that a recently evaluated AI model outperformed clinicians by more than 10% in detecting early-stage melanoma, demonstrating the superior diagnostic accuracy these tools contribute to clinical research.

Key Market Players

  • IQVIA, Inc
  • Aragen Life Sciences Ltd
  • Thermo Fisher Scientific Inc.
  • Parexel International Corporation
  • Charles River Laboratories
  • Icon, Plc
  • Medidata Solutions
  • Syneos Health pvt ltd.
  • S Pharmaron inc.
  • Wuxi Apptec

Report Scope

In this report, the Global Dermatology Contract Research Organization (CRO) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatology Contract Research Organization (CRO) Market, By Type

  • Drug Discovery
  • Preclinical
  • Clinical

Dermatology Contract Research Organization (CRO) Market, By Service Type

  • Laboratory
  • Technology
  • Medical Writing
  • Regulatory/Medical Affairs
  • Others

Dermatology Contract Research Organization (CRO) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatology Contract Research Organization (CRO) Market.

Available Customizations:

Global Dermatology Contract Research Organization (CRO) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermatology Contract Research Organization (CRO) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Drug Discovery, Preclinical, Clinical)
    • 5.2.2. By Service Type (Laboratory, Technology, Medical Writing, Regulatory/Medical Affairs, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Dermatology Contract Research Organization (CRO) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Service Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dermatology Contract Research Organization (CRO) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Service Type
    • 6.3.2. Canada Dermatology Contract Research Organization (CRO) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Service Type
    • 6.3.3. Mexico Dermatology Contract Research Organization (CRO) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Service Type

7. Europe Dermatology Contract Research Organization (CRO) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Service Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dermatology Contract Research Organization (CRO) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Service Type
    • 7.3.2. France Dermatology Contract Research Organization (CRO) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Service Type
    • 7.3.3. United Kingdom Dermatology Contract Research Organization (CRO) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Service Type
    • 7.3.4. Italy Dermatology Contract Research Organization (CRO) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Service Type
    • 7.3.5. Spain Dermatology Contract Research Organization (CRO) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Service Type

8. Asia Pacific Dermatology Contract Research Organization (CRO) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Service Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dermatology Contract Research Organization (CRO) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Service Type
    • 8.3.2. India Dermatology Contract Research Organization (CRO) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Service Type
    • 8.3.3. Japan Dermatology Contract Research Organization (CRO) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Service Type
    • 8.3.4. South Korea Dermatology Contract Research Organization (CRO) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Service Type
    • 8.3.5. Australia Dermatology Contract Research Organization (CRO) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Service Type

9. Middle East & Africa Dermatology Contract Research Organization (CRO) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Service Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dermatology Contract Research Organization (CRO) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Service Type
    • 9.3.2. UAE Dermatology Contract Research Organization (CRO) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Service Type
    • 9.3.3. South Africa Dermatology Contract Research Organization (CRO) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Service Type

10. South America Dermatology Contract Research Organization (CRO) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Service Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dermatology Contract Research Organization (CRO) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Service Type
    • 10.3.2. Colombia Dermatology Contract Research Organization (CRO) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Service Type
    • 10.3.3. Argentina Dermatology Contract Research Organization (CRO) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Service Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dermatology Contract Research Organization (CRO) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. IQVIA, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Aragen Life Sciences Ltd
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Parexel International Corporation
  • 15.5. Charles River Laboratories
  • 15.6. Icon, Plc
  • 15.7. Medidata Solutions
  • 15.8. Syneos Health pvt ltd.
  • 15.9. S Pharmaron inc.
  • 15.10. Wuxi Apptec

16. Strategic Recommendations

17. About Us & Disclaimer